Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: cjgaddy who wrote (780)	12/2/1997 9:32:00 PM
From: shero	Read Replies (1) \| Respond to of 3702

Jack--I don't want to answer for Davis. He'll have alot to say but let me add TCLN is a stock looking for a reason to go up. Despite mgmts ferverent desire to see the stock go back to $2 so they can deal with margin calls again there has been a tremendous amount of "background" publicity for TCLN. All this stuff with Idec helps. Everytime Idec is mentioned more is said about monoclonal antibodies and that lends credibility--TCLN's missing element--to the company. Lets count the reasons this stock should be higher. Not in order. 1) Phase 3 trial for LYM-1 proceeds--with TCLN's new people, who seem to be competent to manage the trial. 2) Phase 1 Glioma trial at Emory. The new people managed to get the job done on time. 3) IND filed for lung cancer 1st quarter 98. 4) New Board of Directors--two oldies gone and Lippman as a positive addition. Remember he has managed lots of clinical trials and this is the type of expertise the company desperately needs. 5) New CEO, hopefully before Christmas. 6) Maybe a deal to cross-license one of TCLNs' technologies--this brings in non-dilutive capital. 7) All the other things I don't know about. Reasons the stock should go down--Tax selling which will be over soon. That's the story as I see it now. Davis will have more to add. BTW call the PR department at TCLN--714-838-0500--for a copy of the Hanifen report. If you get the usual mealy mouth answer about why they can't send it to you call Hanifen at 303-291-5456. Its not a detailed report but a follow-up of one written some time ago. I hear that as soon as a new CEO is appointed a more detailed report will follow.